| Prev Close | 170.59 |
| Open | 170.86 |
| Day Low/High | 169.30 / 170.99 |
| 52 Wk Low/High | 151.47 / 179.92 |
| Volume | 3.16M |
Johnson & Johnson (JNJ)
170.00
0.59
0.35
NYSE
| Exchange | NYSE |
| Shares Outstanding | 2632.60B |
| Market Cap | 443.28B |
| P/E Ratio | 28.74 |
| Div & Yield | N.A. (N.A) |
Johnson & Johnson Remains Dividend Stock Royalty
Despite recent talc powder risks, the long-term earnings power of this 'Dividend King' has not deteriorated.
Jim Cramer: This Is a Treacherous Bear Market
But even in bear markets you get spikes, usually short sharp ones.
It's Ugly Out There: Here's What I Suggest Traders Do Right Now
We are absolutely due for a rip-your-face-off rally in the wake of entering a bear market.
Now Is the Time to Play Defense
Remember, though, playing defense is very different than leaving the stadium altogether.
Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center
These are currently situations where companies are facing serious lawsuits.
Are Algos Jumping on J&J Headlines?
Are machines jumping on Johnson & Johnson's human risk headlines?
Chart of the Day: Johnson & Johnson's Punishment Appears Overdone
Putting J&J stock's selloff in a graphic illustrates the market's swift and violent reaction to the Reuters report.
Johnson & Johnson Challenges Reuters' Assertions About Its Product Safety
Shares continue to fall on Monday after Friday's swift descent.
Let's Get Real About Johnson & Johnson's Selloff and How to Play the Stock
I find a lot of Reuters' claims hard to believe. Even more difficult to believe is the selloff.
Johnson & Johnson Stock Presents a Buying Opportunity Amid an Overblown Selloff
Many analysts advise buying the shares on weakness because it's attractively priced.
Johnson & Johnson - Round 2 - More Selling Pressure
JNJ ended the day and week in a vulnerable position and we are seeing further weakness today.
Interest in Johnson & Johnson Stock Dries Up Amid Baby Powder Scandal
The market appears to still be spooked by JNJ as shares are set to open at their lowest level since July amid the Reuters articles fallout.
Jim Cramer: Trust This Market? It Remains Treacherous
Now the unnerving thing about this market is that when it gets on a negative roll it blows through all convention.
Investors No Longer Trust Growth, Plus How to Play JNJ: Market Recon
While headline-chasing algorithms alter expected outcomes based on fundamental analysis, technical analysis remains valid.
Johnson & Johnson Breaks Down Sharply on the Charts So Take Action
Johnson & Johnson has survived some unfortunate news events in the past, but I would not take that as a good technical reason to hold the stock.
Jim Cramer: I Can't Tell You to Buy This Market
I am urging you to think a little more long-term.
Helmets and Flak Jackets
Unimpressed Equity markets headed lower as the regular Friday trading session extended into it's second and third hours. The way down has been led, not by Adobe , not by Costco , but by Johnson & Johnson . I have been known to make limited attempts ...
Jim Cramer: The Operative Term for This Tape Is Treacherous
Use it to your advantage or don't use it at all.
Jim Cramer: Don't Throw Away These Stocks
It's done without much thought even though their companies are doing amazingly well.
3 Tips for Trading the Fed's More Dovish Stance
Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?
This Black Friday, Any Rally Will Be Light: Market Recon
With all the major indices trading below 50-day moving averages, it would take a big move up to be meaningful.
Pfizer Shares Jump on Monday After Company Signals Higher Price Push
Pfizer pushes higher on price increases.
Bulls Stampeded by Bears as FAANG Stocks Get Trampled
A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.
Tech Selloff Could Work in Favor of Pharmaceutical Stocks
Pharma could be the best parking spot for your money if the market keeps trending downward.
Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Eli Lilly's Elanco Offload Offers Acquisition Flexibility
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
